Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 7, 1997, Pages 1444-1448

  Innaimo, Steven F ^a   Seifer, Maria ^a   Bisacchi, Gregory S ^a   Standring, David N ^a   Zahler, Robert ^a   Colonno, Richard J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DEOXYGUANOSINE DERIVATIVE; ENTECAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG POTENCY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0030872946     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.7.1444     Document Type: Article

References (31)

1. Beasley, R. P., and L. Y. Hwang. 1991. Overview on the epidemiology of hepatocellular carcinoma, p. 532-535. In F. B. Hollinger, S. M. Lemon, and M. Margolis (ed.), Viral hepatitis and liver disease. The Williams & Willkins Co., Baltimore, Md.
2. Bisacchi, G. S., S. T. Chao, C. Bachard, J. P. Daris, S. F. Innaimo, J. A. Jacobs, O. Kocy, P. Lapointe, A. Martel, Z. Merchant, W. A. Slusarchyk, J. E. Sundeen, M. G. Young, R. Colonno, and R. Zahler. 1997. BMS-200475, a novel carbocyclic 2′-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro. Bioorg. Med. Chem. Lit. 7:127-132.
3. Boucher, C. A., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
4. Chen, C. H., and Y. C. Cheng. 1989. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J. Biol. Chem. 264:11934-11937.
5. Cui, L., S. Yoon, R. F. Schinazi, and J. P. Sommadossi. 1995. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J. Clin. Invest. 95:555-563.
6. Davis, M. G., J. E. Wilson, N. A. VanDraanen, W. H. Miller, G. A. Freeman, S. M. Daluge, F. L. Boyd, A. E. Aulabaugh, G. R. Painter, and L. R. Boone. 1996. DNA polymerase activity of hepatitis B virus particles: differential inhibition by L-enantiomers of nucleotide analogs. Antivir. Res. 30:133-145.
7. Dienstag, J. L., R. P. Perrillo, E. R. Schiff, M. Bartholomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661.
8. Field, A. K., A. V. Tuomari, B. McGeever-Rubin, B. J. Terry, K. E. Mazina, M. L. Haffey, M. E. Hagen, J. M. Clark, A. Braitman, W. A. Slusarchyk, et al. 1990. (+-)-(1 alpha,2 beta, 3 alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl] guanine [(+-)-BHCG or SQ 33,054]: a potent and selective inhibitor of herpesviruses. Antivir. Res. 13:41-52.
9. Flint, O. Unpublished data.
10. Ganem, D., and H. E. Varmus. 1987. The molecular biology of the hepatitis B viruses. Annu. Rev. Biochem. 56:651-693.
11. Grellier, L., D. Mutimer, M. Ahmed, D. Brown, A. K. Burroughs, K. Rolles, P. McMaster, P. Beranek, F. Kennedy, H. Kibbler, P. McPhillips, E. Elias, and G. Dusheiko. 1996. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348:1212-1215.
12. Hamatake, R. Unpublished data.
13. Honkoop, P., and R. A. deMan. 1995. Clinical aspects of nucleoside analogues for chronic hepatitis B. Int. Antivir. News 3:78-80.
14. Kajino, K., A. R. Jilbert, J. Saputelli, C. E. Aldrich, J. Cullen, and W. S. Mason. 1994. Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J. Virol. 68:5792-5803.
15. Korba, B. E., and M. R. Boyd. 1996. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob. Agents Chemother. 40:1282-1284.
16. Korba, B. E., and G. Milman. 1991. A cell culture assay for compounds which inhibit hepatitis B virus replication. Antivir. Res. 15:217-228.
17. Lee, B., W. X. Luo, S. Suzuki, M. J. Robins, and D. L. Tyrrell. 1989. In vitro and in vivo comparison of the abilities of purine and pyrimidine 2′,3′-dideoxynucleosides to inhibit duck hepadnavirus. Antimicrob. Agents Chemother. 33:336-339.
18. Ling, R., D. Mutimer, M. Ahmed, E. H. Boxall, E. Elias, G. M. Dusheiko, and T. J. Harrison. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713.
19. Luo, G.-X., R. J. Colonno, and M. Krystal. 1997. Characterization of a hemagglutinin-specific inhibitor of influenza A virus. J. Virol. 71:4062-4070.
20. Parker, W. B., and Y. C. Cheng. 1994. Mitochondrial toxicity of antiviral nucleoside analogs. J. NIH Res. 6:57-61.
21. Perrillo, R. P., E. R. Schiff, G. L. Davis, H. C. Bodenheimer, Jr., K. Lindsay, J. Payne, J. L. Dienstag, C. O'Brien, C. Tamburro, I. M. Jacobson, et al. 1990. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N. Engl. J. Med. 323:295-301.
22. Price, P. M., R. Banerjee, A. M. Jeffrey, and G. Acs. 1992. The mechanism of inhibition of hepatitis B virus replication by the carbocyclic analog of 2′-deoxyguanosine. Hepatology 16:8-12.
23. Sells, M. A., M. L. Chen, and G. Acs. 1987. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA 84:1005-1009.
24. Slusarchyk, W. A., A. K. Field, J. A. Greytok, P. Taunk, A. V. Tooumari, M. G. Young, and R. Zahler. 1992. 4-Hydroxy-3-(hydroxymethyl)-2-methyl-cyclopentyl purines and pyrimidines, a novel class of anti-herpesvirus agents. Abstract from the Fifth International Conference on Antiviral Research. Antivir. Res. 17(Suppl. 1):98.
25. Southern, E. M. 1975. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98:503-517.
26. Suzuki, S., B. Lee, W. Luo, D. Tovell, M. J. Robins, and D. L. Tyrrell. 1988. Inhibition of duck hepatitis B virus replication by purine 2′,3′-dideoxynucleosides. Biochem. Biophys. Res. Commun. 156:1144-1151.
27. Tamura, K., and T. Aotsuka. 1988. Rapid isolation method of animal mitochondrial DNA by the alkaline lysis procedure. Biochem. Genet. 26:815-819.
28. Tipples, G. A., M. M. Ma, K. P. Fischer, V. G. Bain, N. M. Kneteman, and D. L. Tyrrell. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717.
29. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
30. Weislow, O. S., R. Kiser, D. L. Fine, J. Bader, R. H. Shoemaker, and M. R. Boyd. 1989. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81:577-586.
31. World Health Organization. 1996. Executive summary. In World Health Report 1996. World Health Organization, Geneva, Switzerland.